Oruka Therapeutics
ORKA
15 hedge funds and large institutions have $958K invested in Oruka Therapeutics in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 5 closing their positions.
0.03% less ownership
Funds ownership: 0.08% → 0.06% (-0.03%)
12% less funds holding
Funds holding: 17 → 15 (-2)
23% less capital invested
Capital invested by funds: $1.24M → $958K (-$283K)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$26.4K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$25.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$2.82K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.11K |
| 5 |
Morgan Stanley
New York
|
+$939 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$175K |
| 2 |
RA
Royce & Associates
New York
|
-$163K |
| 3 |
Renaissance Technologies
New York
|
-$62.1K |
| 4 |
VF
Virtu Financial
New York
|
-$18.4K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$16K |
ORKA Hedge Fund Activity: Q2 2018 in Review
15 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q2 2018, worth a combined $958K — down 23% from $1.24M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ORKA and 3 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 2 added.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $26.4K. The largest seller was Deutsche Bank, exiting entirely with an estimated $175K sold.
- 15 institutional investors held Oruka Therapeutics (ORKA) as of Q2 2018, down from 17 in Q1 2018.
- Funds reported $958K of Oruka Therapeutics stock for Q2 2018, down 23% quarter-over-quarter.
- 3 funds opened new Oruka Therapeutics positions in Q2 2018 and 5 closed out, a net change of -2 holders.
- The largest Oruka Therapeutics buyer in Q2 2018 was Geode Capital Management, an estimated $26.4K added.
- The largest Oruka Therapeutics seller in Q2 2018 was Deutsche Bank, an estimated $175K sold.
Based on aggregated 13F filings for Q2 2018.